Physician profile
Javan S Bass
NPI 1669601381
$43,227.72
in general payments reported to CMS, 2019-2025
35 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 80% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $4,310 · 2021: $8,866 · 2022: $6,964 · 2023: $2,954 · 2024: $3,422 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,919 · Consulting Fee: $1,550 · Travel and Lodging: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,919.19 |
| Consulting Fee | $1,550.00 |
| Travel and Lodging | $1,536.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amniox Medical, INC. | $17,420.43 | 2019-2020 | |
| Biotissue Holdings INC. | $11,362.03 | 2019-2024 | |
| Grt US Holding, INC. | $5,052.40 | 2022 | |
| Treace Medical Concepts, INC. | $2,776.36 | 2021-2025 | |
| United Orthopedics LLC | $1,200.00 | 2021 | |
| Smith+Nephew, INC. | $1,181.87 | 2019-2025 | Grafix Pl, Stravix Pl, Grafix |
| Anika Therapeutics, INC. | $752.80 | 2023 | Fna Products |
| Organogenesis INC. | $695.30 | 2019-2025 | Puraply Wound Matrix, Affinity, Via Matrix |
| Stryker Corporation | $627.24 | 2019-2025 | Salvation, Augment Injectable, Asnis |
| Convatec INC. | $302.80 | 2023-2024 | |
| Osiris Therapeutics INC. | $247.76 | 2019 | |
| 4web, INC. | $173.24 | 2019 | |
| Paragon 28, INC. | $166.50 | 2019-2024 | Joust Beaming |
| Kerecis Limited | $163.59 | 2022-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Flower Orthopedics Coporation | $147.80 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $139.84 | 2019 | |
| Triad Life Sciences INC. | $138.56 | 2022 | |
| Acell, INC. | $120.88 | 2020 | |
| Linvatec Corporation | $120.64 | 2023 | Colink Mfx, Fracture and Correction Colag 2, Colink Afx |
| Averitas Pharma INC. | $67.53 | 2024-2025 | Qutenza |
| Depuy Synthes Sales INC. | $54.33 | 2023-2024 | Va-Lcp, Na |
| Dynasplint Systems INC. | $34.26 | 2019-2023 | Dynasplint |
| Bioventus LLC | $33.65 | 2023 | |
| Surgenex LLC | $31.11 | 2025 | Surgraft, Surmatrix, Pellograft |
| Globus Medical, INC. | $26.45 | 2025 | Senza |
| Vertex Pharmaceuticals Incorporated | $24.07 | 2025 | |
| Zyla Life Sciences, INC. | $22.22 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.63 | 2025 | Nuzyra |
| Melinta Therapeutics, LLC | $20.57 | 2022 | |
| Orthofix Medical, INC. | $19.92 | 2019-2021 | |
| Kci USA, INC. | $19.03 | 2019 | |
| Nevro Corp. | $18.46 | 2022 | |
| Solventum Corporation | $16.63 | 2025 | 3m Cavilon, Activ.A.C., V.A.C. Granufoam |
| Tenex Health INC. | $14.96 | 2019 | |
| Biocomposites INC | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javan Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.